The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer

Psycho-Oncology

Volumn 18, Issue 2, 2009, Pages 156-161

  Fan, H G Mar ^a,b   Park, A ^a   Xu, W ^a   Yi, Q L ^a   Braganza, S ^a   Chang, J ^c   Couture, F ^d   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c LAKERIDGE HEALTH CORPORATION   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Breast cancer; Chemotherapy; Cognitive function; Epoetin alfa; Quality of life

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; TAXANE DERIVATIVE; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ANXIETY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER FATIGUE; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; FUNCTIONAL ASSESSMENT; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LEARNING TEST; MAJOR CLINICAL STUDY; MOOD; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; BREAST TUMOR; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; FATIGUE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COGNITION DISORDERS; EPOETIN ALFA; FATIGUE; FEMALE; HEMATINICS; HUMANS; MATCHED-PAIR ANALYSIS; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 66149148376     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1372     Document Type: Article

References (33)

1. Ahles TA, Saykin AJ, Furstenberg CT et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485-493.
2. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695-2701.
3. Mar Fan HG, Houede-Tchen N, Yi QL et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005;23:8025-8032.
4. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-650
5. Tchen N, Juffs HG, Downie FP et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003;21:4175-4183.
6. van Dam FS, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-218.
7. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004;100:2292-2299.
8. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995;4:61-66.
9. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004;22: 2233-2239.
10. Fallowfield L, Gagnon D, Zagari M et al, Epoetin Alfa Study Group. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002;87:1341-1353
11. Hudis CA, Vogel CL, Gralow JR, Williams D. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. Clin Breast Cancer 2005;6:132-142.
12. Savonije JH, van Groeningen CJ, van Bochove A et al. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial. Eur J Cancer 2005;41:1560-1569.
13. Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005; 23:2606-2617.
14. Bernaudin M, Bellail A, Marti HH et al. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 2000;30:271-278.
15. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-10531.
16. Ehrenreich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
17. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997;76:105-116.
18. Siren AL, Fratelli M, Brines M et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001;98: 4044-4049.
19. O'Shaughnessy JA, Vukelja SJ, Holmes FA et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005;5:439-446.
20. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23: 2597-2605.
21. Bleecker ML, Bolla-Wilson K, Kawas C, Agnew J. Age-specific norms for the Mini-Mental State Exam. Neurology 1988;38:1565-1568.
22. Kukull WA, Larson EB, Teri L, Bowen J, McCormick W, Pfanschmidt ML. The Mini-Mental State Examination score and the clinical diagnosis of dementia. J Clin Epidemiol 1994;47:1061-1067.
23. Fogel BS. The high sensitivity cognitive screen. Int Psychogeriatr 1991;3:273-288.
24. Benedict RH, Zgaljardic DJ. Practice effects during repeated administrations of memory tests with and without alternate forms. J Clin Exp Neuropsychol 1998; 20:339-352.
25. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63-74.
26. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11:570-579.
27. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67: 361-370.
28. Xenocostas A, Cheung WK, Farrell F et al The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 2005;61: 189-195.
29. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999;33:1122-1130.
30. Stivelman JC. Benefits of anaemia treatment on cognitive function. Nephrol Dial Transplant 2000; 15(Suppl. 3):29-35.
31. Newton NR, Leonard CH, Piecuch RE, Phibbs RH. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J Perinatol 1999;19:403-406.
32. Gisselbrecht C, Tesch H, Jourdan E, Avvisati G, Tsatalas C, Marschner N. Cognitive effects of once weekly epoetin alfa in anemic patients with hematologic malignancies receiving chemotherapy: interim results of the EPOLYM trial. Blood 2004;104:Abstract 2217.
33. Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 2003;9:967-982.